Related Experiment Video
Updated: Mar 28, 2026

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
Low-dose aspirin as an adjuvant treatment for venous leg ulceration: study protocol for a randomized controlled trial
Andrew Jull1,2, Angela Wadham2, Chris Bullen2
1School of Nursing, University of Auckland, New Zealand.
Aim:
The aim of this study was to determine the effect of low-dose aspirin on venous leg ulcer healing when used in addition to compression.
Background:
The mainstay of treatment for venous leg ulcers is compression therapy and there are few adjuvant treatments to accelerate healing.
Design:
Pragmatic, community-based, double-blind, randomized trial.
Methods:
Participants with venous leg ulcers will receive either 150 mg aspirin or placebo daily for up to 24 weeks. Participants will receive background treatment with compression therapy (system of choice guided by participant and/or clinical preference) delivered through district nursing services. The primary outcome will be time-to-healing. Secondary outcomes will include proportion healed at 24 weeks, change in ulcer area, change in health-related quality of life, adherence, efficacy of blinding and adverse events. The trial was funded in June 2014.
Discussion:
The trial commenced in March 2015 and is successfully recruiting. The trial is one of three trials that will contribute to an individual participant data meta-analysis to be undertaken at the York Trials Centre.
Trial Registration:
Registered 5 June 2014 ClinicalTrials.gov NCT02158806. Protocol version 1·1, 14 April 2015.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

